• KOL
    • Gastroesophageal Reflux
    • Donald O Castell
    • Donald O Castell: Influence Statistics

      Donald O Castell

      Donald O Castell

      Show email address

      Division of Gastroenterology and Hepatology, Medical University of South Carolina, Charleston, South Carolina, USA | Medical University of South Carolina, Charleston, South ...

      Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

      Donald O Castell:Expert Impact

      Concepts for whichDonald O Castellhas direct influence:Gastroesophageal reflux,Chest pain,Gastroesophageal reflux disease,Esophageal manometry,Nutcracker esophagus,Esophageal motility,Acid reflux,Lower esophageal sphincter.

      Donald O Castell:KOL impact

      Concepts related to the work of other authors for whichfor which Donald O Castell has influence:Gastroesophageal reflux,Chest pain,Esophageal motility,Proton pump,Chronic cough,Gerd patients,Hiatal hernia.

      KOL Resume for Donald O Castell

      Year
      2021

      Division of Gastroenterology and Hepatology, Medical University of South Carolina, Charleston, South Carolina, USA

      2020

      Medical University of South Carolina, Charleston, South Carolina, USA

      2019

      Medical University of South Carolina, Division of Gastroenterology, Charleston, SC, USA

      2018

      Medical University of South Carolina, Charleston, SC, USA

      Department of Gastroenterology and Hepatology.

      2017

      Esophageal Disorders Program, Division of Gastroenterology and Hepatology, Medical University of South Carolina-MUSC, Charleston, South Carolina, USA

      Division of Gastroenterology and Hepatology, Medical University of South Carolina, Charleston

      2016

      Esophageal Disorders Program, Medical University of South Carolina, Charleston, South Carolina, USA

      Division of Gastroenterology & Hepatology, Medical University of South Carolina, Charleston, South Carolina

      2015

      Esophageal Disorders Program, Division of Gastroenterology and Hepatology, Medical University of South Carolina, Charleston

      2013

      Esophageal Disorders Program, Medical University of South Carolina, 25 Courtenay Drive, 29425, Charleston, SC, USA

      Divisions of Gastroenterology and Hepatology

      2012

      Medical University of South Carolina, Division of Gastroenterology and Hepatology, Charleston, South Carolina, USA

      Digestive Disease Center Gastroenterology and Hepatology

      2010

      Gastroenterology and Hepatology, MUSC, Charleston, SC, USA

      2009

      Digestive Diseases Center, Medical University of South Carolina, Charleston, South Carolina, USA

      Division of Gastroenterology, Medical University of South Carolina, Charleston, SC

      2008

      Digestive Diseases Center, Medical University of South Carolina, Charleston, SC

      Division of Gastroenterology, Medical University of South Carolina, Charleston, South Carolina;

      2007

      Digestive Disease Center, Medical University of South Carolina, Charleston, South Carolina, USA

      Division of Gastroenterology, Medical University of South Carolina, Charleston, SC,

      2006

      Division of Gastroenterology–Hepatology, Medical University of South Carolina, Charleston, South Carolina

      Centre of Gastroenterological Research, Catholic University of Leuven, Belgium

      2005

      Department of Surgery, Medical University of South Carolina, Charleston, USA

      Digestive Diseases Center, Medical University of South Carolina, Charleston, South Carolina

      2004

      Division of Gastroenterology/Hepatology, Medical University of South Carolina, South Carolina

      Departments of Medicine

      2003

      Division of Gastroenterology and Hepatology, Medical University of South Carolina, 96 Jonathan Lucas Street, Suite 210, CSB, Charleston, SC 29425, USA

      Department of Gastroenterology and Hepatology, Medical University of South Carolina, Charlston, South Carolina

      2002

      From the Division of Gastroenterology and Hepatology, Medical University of South Carolina, Charleston, South Carolina, U.S.A.

      Palo Alto, San Francisco, and Stanford, California, Omaha, Nebraska, Ann Arbor, Michigan, Dallas, Texas, Boston, Massachusetts, Lebanon, New Hampshire, Louisville, Kentucky, Rochester, New York, Denver, Colorado, St. Louis, Missouri, and Philadelphia, Pennsylvania

      Graduate Hospital, Esophageal Laboratory, Philadelphia, PA, USA

      Sign-in to see all concepts, it's free!
      Sample of concepts for which Donald O Castell is among the top experts in the world.
      Concept World rank
      lansoprazole drug #1
      amine oxidase method #1
      oesophagus dysphagia #1
      impedance segments #1
      refluxate presence #1
      esophagitis cats #1
      motility abnormality asthma #1
      oval round catheters #1
      progressivedysphagia #1
      gerd nonparametric surveys #1
      differential esophageal spasm #1
      esophagology #1
      dea liquid #1
      patients manometric diagnosis #1
      methods pneumatic dilation #1
      lansoprazole gastric acid #1
      airway obstruction achalasia #1
      impedance transit defects #1
      beforedilatation symptom scores #1
      bedtime h2blocker #1
      combined manometry mii #1
      water btt #1
      decreases reflux #1
      pge1 infusion studies #1
      h2ra percentage time #1
      achalasia bolus #1
      meal periods #1
      lidocaine inhibition pressure #1
      multichannel intraluminal impedance #1
      liquid solid boluses #1
      proximal distal esophagus #1
      329±036 #1
      reflux postprandial exercise #1
      release omeprazole pantoprazole #1
      esophageal inflammation cats #1
      esophageal impedance values #1
      tlesrs higher percentage #1
      achalasia single #1
      meal 2 hours #1
      time acidity #1
      10 20 ranitidine #1
      spdr positioning device #1
      reflux episodes positive #1
      deglutitive inhibition pairs #1
      swallows oesophageal pressures #1
      reflux positive scans #1
      cisapride 2 #1
      pirenzepine 25 50 #1
      studies pneumatic dilation #1
      scleroderma esophagus #1
      Sign-in to see all concepts, it's free!

      Prominent publications by Donald O Castell

      KOL-Index: 17546

      AIM: Proton pump inhibitors taken twice daily before meals (proton pump inhibitor b.d. AC) effectively controls daytime gastric pH; however, nocturnal gastric acid breakthrough (NAB) occurs in more than 75% of patients. Adding an H2-blocker at bedtime decreases NAB in normal subjects. The efficacy of this regimen has not been evaluated in GERD patients. The aim of this study was to assess the effects of proton pump inhibitor b.d., both with and without bedtime H2-blocker on intragastric ...

      Known for Gerd Patients | Proton Pump | Gastric Acid | Bedtime Nab | Percentage Time
      KOL-Index: 17303

      OBJECTIVES: Esomeprazole, the S isomer of omeprazole, has been shown to have higher healing rates of erosive esophagitis than omeprazole. This study compared esomeprazole with lansoprazole for the healing of erosive esophagitis and resolution of heartburn.

      METHODS: This United States multicenter, randomized, double blind, parallel group trial was performed in 5241 adult patients (intent-to-treat population) with endoscopically documented erosive esophagitis, which was graded by severity ...

      Known for Erosive Esophagitis | Esomeprazole Lansoprazole | Healing Rates | Sustained Resolution | Heartburn Patients
      KOL-Index: 16506

      BACKGROUND AND AIMS: Empiric proton pump inhibitor (PPI) trials have become increasingly popular leading to gastroenterologists frequently evaluating gastro-oesophageal reflux disease (GORD) patients only after they have "failed" PPI therapy. Combined multichannel intraluminal impedance and pH (MII-pH) monitoring has the ability to detect gastro-oesophageal reflux (GOR) episodes independent of their pH and evaluate the relationship between symptoms and all types of GOR. Using this ...

      Known for Acid Reflux | Persistent Symptoms | Patients Ppis | Ambulatory Impedance | Ppi Therapy
      KOL-Index: 16228

      BACKGROUND & AIMS: Proton pump inhibitors administered twice daily do not provide complete nocturnal acid suppression. Acid breakthrough, or decrease in intragastric pH to <4 for an hour or longer, occurs in three quarters of normal subjects and patients at night. We compared the effect of a third dose of omeprazole at bedtime with that of a dose of ranitidine at bedtime on residual nocturnal acid secretion in patients receiving omeprazole twice daily.

      METHODS: Twelve volunteers ...

      Known for Acid Breakthrough | Ranitidine Bedtime | Nocturnal Gastric | Omeprazole Placebo | Percentage Time
      KOL-Index: 14694

      BACKGROUND: Nocturnal gastric acid breakthrough, defined as intragastric pH < 4 for more than 1 h in the overnight period, is observed in up to 70% of normal subjects on proton pump inhibitors taken twice daily. The frequency of this breakthrough in patients with gastro-oesophageal reflux and accompanying oesophageal reflux during this period has not been studied.

      AIM: To examine the frequency of nocturnal break-through and accompanying oesophageal acid exposure in patients with ...

      Known for Oesophageal Reflux | Proton Pump | Gastric Acid | Barretts Oesophagus | Breakthrough Patients
      KOL-Index: 12769

      BACKGROUND: In patients with severe gastro-oesophageal reflux disease (GERD), proton pump inhibitors are being used increasingly in twice-daily regimens to improve control of gastric acidity. Few data exist to compare the ability of the most-often used proton pump inhibitors, omeprazole and lansoprazole, to control gastric acid at twice-daily dosage regimens. Nocturnal acid breakthrough, defined as gastric pH < 4.0 continuously for > 60 min, may compromise treatment goals in patients ...

      Known for Gastric Acidity | Acid Breakthrough | Omeprazole 20 | Patients Gerd | Lansoprazole 30
      KOL-Index: 12451

      BACKGROUND: Persistent symptoms on acid suppressive therapy are due to either acid or nonacid gastroesophageal reflux (GER) episodes or are not related to reflux.

      AIM: To compare physical and chemical characteristics of GER episodes associated with symptoms in patients on acid suppressive therapy.

      METHODS: Patients with persistent symptoms on acid suppressive therapy underwent combined impedance-pH monitoring. Reflux episodes were classified as acid if nadir pH was <4.0, and nonacid if ...

      Known for Reflux Episodes | Acid Suppressive Therapy | Symptoms Patients | Proximal Esophagus | Liquid Mixed
      KOL-Index: 12129

      BACKGROUND & AIMS: Combined multichannel intraluminal impedance and manometry (MII-EM) assesses esophageal function by simultaneous measurement of both pressure and bolus transit. Normative data for this method have not been published. The aim of this study was to establish normative data for combined MII-EM and to correlate liquid and viscous bolus transit by impedance with esophageal contractions by manometry.

      METHODS: Forty-three normal volunteers recruited from 4 centers (15 women, ...

      Known for Esophageal Function | Combined Miiem | Complete Bolus Transit | Normative Data | Intraluminal Impedance
      KOL-Index: 12029

      BACKGROUND: In this multi-center study, the feasibility, safety, and efficacy of radiofrequency (RF) energy delivery to the gastroesophageal junction (GEJ) for the treatment of gastroesophageal reflux disease (GERD) were investigated.

      METHODS: Forty-seven patients with classic symptoms of GERD (heartburn and/or regurgitation), a daily anti-secretory medication requirement, and at least partial symptom response to drugs were enrolled. All patients had pathologic esophageal acid exposure ...

      Known for Gastroesophageal Junction | Energy Delivery | 6 Months | Treatment Gerd | Quality Life
      KOL-Index: 12021

      OBJECTIVE: The association of gastroesophageal reflux disease (GERD) and respiratory symptoms is well known. The coexistence of ineffective esophageal motility (IEM, low-amplitude [< 30 mm Hg] or nontransmitted contractions in > or = 30% of 10 wet swallows in the distal esophagus) in patients with GERD has recently been demonstrated. Our aim was to determine the prevalence of IEM in patients with GERD-associated respiratory symptoms.

      METHODS: Manometry and pH studies of 98 consecutive ...

      Known for Respiratory Symptoms | Ineffective Esophageal Motility | Iem Patients | Chronic Cough Asthma | Abnormal Reflux
      KOL-Index: 11794

      BACKGROUND & AIMS: Combined multichannel intraluminal impedance (MII) and manometry (MII-EM) recently became available as an esophageal function test. Initial studies in healthy volunteers have shown that a proportion of ineffective contractions actually have complete bolus transit. The aim of our study is to evaluate esophageal bolus transit in patients with manometric patterns of ineffective esophageal motility (IEM).

      METHODS: All patients referred for esophageal function testing ...

      Known for Esophageal Function | Combined Impedance | Viscous Swallows | Manometric Diagnosis | Transit Patients
      KOL-Index: 11511

      BACKGROUND: On chronic intake of omeprazole, most healthy volunteers and patients still have nocturnal acid breakthrough (NAB), defined as night-time periods with gastric pH < 4.0 lasting for longer than 1 h. Gastro-oesophageal reflux during NAB may be particularly injurious to the oesophageal mucosa, contributing to the chronic lesions complicating the condition.

      AIM: To compare the effect of three different dosing regimens of omeprazole 40 mg daily with regard to suppressing nocturnal ...

      Known for Gastric Acidity | Acid Breakthrough | Breakfast Dinner | Percentage Time | Regimens Omeprazole
      KOL-Index: 11389

      BACKGROUND: Achalasia is defined manometrically by an aperistaltic esophagus. Variations in the manometric findings occur in achalasia suggesting that all manometric features should not be required to diagnose achalasia. Combined multichannel intraluminal impedance and esophageal manometry (MII-EM) allows both a functional and a manometric evaluation of esophageal motility and identifies chronic fluid retention.

      AIM: To compare manometric and MII characteristics in patients with ...

      Known for Achalasia Patients | Esophageal Manometry | Mm Hg | Aged Pressure | Manometric Evaluation

      Key People For Gastroesophageal Reflux

      Top KOLs in the world
      #1
      John Dent
      reflux disease gastric emptying pyloric motility
      #2
      Donald O Castell
      gastroesophageal reflux chest pain esophageal manometry
      #3
      Peter James Kahrilas
      esophagogastric junction chicago classification gastroesophageal reflux disease
      #4
      Tom R DeMeester
      gastroesophageal reflux intestinal metaplasia esophageal adenocarcinoma
      #5
      Joel E Richter
      chest pain gastroesophageal reflux eosinophilic esophagitis
      #6
      Hashem B EL‐SERAG
      united states hepatocellular carcinoma veterans affairs

      Division of Gastroenterology and Hepatology, Medical University of South Carolina, Charleston, South Carolina, USA | Medical University of South Carolina, Charleston, South Carolina, USA | Department of Internal Medicine, Medical University of South

    Download on the App StoreGet it on Google Play

    Copyright © 2023 Key Opinion Leaders, LLC.